Covid-19 vaccine sales fall on uncertain demand and supply surplus of rival shots
19 April 2022 - 16:54
byManas Mishra
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Bengaluru — Johnson & Johnson (J&J) on Tuesday cut its full-year profit expectation and suspended sales forecast for its Covid-19 vaccine after having earlier predicted as much as $3.5bn in sales from the shot.
The world’s largest healthcare conglomerate cited uncertain demand and supply surplus of rival shots that have fared much better than its single-dose vaccine for cancelling the forecast.
The vaccine, which is sold at a “not-for-profit” price, brought in $457m in the first quarter. Its sales last year had underperformed rival mRNA shots also due to manufacturing bottlenecks and safety concerns.
Pfizer has forecast $32bn in 2022 sales from its Covid vaccine developed with BioNTech, while Moderna has forecast $21bn.
J&J said it now expects full-year adjusted profit forecast to be $10.15-$10.35 per share, lower than the prior forecast of $10.40- $10.60. Overall sales of $23.43bn in the first quarter missed Refinitiv estimates of $23.61bn.
“The slight miss was really around the Covid-19 vaccine and quite frankly it met our internal expectations. There was just a disconnect into how the Street assumed it was going to play out over the year,” CFO Joseph Wolk told CNBC.
Last year, production at the Maryland plant of its contract manufacturer Emergent BioSolutions was halted by the US Food and Drug Administration as an accidental mix-up of ingredients ruined about 15-million vaccine doses.
The New York Times had reported in February that J&J shut down the only plant making usable batches of its Covid-19 vaccine late last year.
Excluding items, J&J earned $2.67 per share, beating market expectation of $2.56 per share.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Johnson & Johnson cuts annual profit forecast
Covid-19 vaccine sales fall on uncertain demand and supply surplus of rival shots
Bengaluru — Johnson & Johnson (J&J) on Tuesday cut its full-year profit expectation and suspended sales forecast for its Covid-19 vaccine after having earlier predicted as much as $3.5bn in sales from the shot.
The world’s largest healthcare conglomerate cited uncertain demand and supply surplus of rival shots that have fared much better than its single-dose vaccine for cancelling the forecast.
The vaccine, which is sold at a “not-for-profit” price, brought in $457m in the first quarter. Its sales last year had underperformed rival mRNA shots also due to manufacturing bottlenecks and safety concerns.
Pfizer has forecast $32bn in 2022 sales from its Covid vaccine developed with BioNTech, while Moderna has forecast $21bn.
J&J said it now expects full-year adjusted profit forecast to be $10.15-$10.35 per share, lower than the prior forecast of $10.40- $10.60. Overall sales of $23.43bn in the first quarter missed Refinitiv estimates of $23.61bn.
“The slight miss was really around the Covid-19 vaccine and quite frankly it met our internal expectations. There was just a disconnect into how the Street assumed it was going to play out over the year,” CFO Joseph Wolk told CNBC.
Last year, production at the Maryland plant of its contract manufacturer Emergent BioSolutions was halted by the US Food and Drug Administration as an accidental mix-up of ingredients ruined about 15-million vaccine doses.
The New York Times had reported in February that J&J shut down the only plant making usable batches of its Covid-19 vaccine late last year.
Excluding items, J&J earned $2.67 per share, beating market expectation of $2.56 per share.
Reuters
AstraZeneca’s oncology credentials boost its big pharma status
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Russian firms and global banks set for windfall from depositary receipt ...
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.